Background. A combination of TLR9 agonists and an anti-PD-1 antibody has been reported to be effective in immunocompetent mice but the role of innate immunity has not yet been completely elucidated. Therefore, we investigated the contribution of the innate immune system to this combinatorial immunotherapeutic regimens using an immunodeficient mouse model in which the effector functions of innate immunity can clearly emerge without any interference from T lym-phocytes. Methods. Athymic mice xenografted with IGROV-1 human ovarian cells, reported to be sensitive to TLR9 agonist therapy, were treated with cytosine–guanine (CpG)-oligodeoxynucleo-tides (ODNs), an anti-PD-1 antibody or their combination. Results. We found that PD-1 blockade dampened CpG-ODN antitumor activity. In vitro studies indicated that the interaction between the anti-PD-1 antibody fragment crystallizable (Fc) domain and macrophage Fc receptors caused these immune cells to acquire an immunoregulatory phenotype, contributing to a decrease in the efficacy of CpG-ODNs. Accordingly, in vivo macrophage depletion abrogated the detrimental effect exerted by the anti-PD-1 antibody. Conclusion. Our data suggest that if TLR signaling is active in macro-phages, coadministration of an anti-PD-1 antibody can reprogram these immune cells towards a polarization state able to negatively affect the immune response and eventually promote tumor growth.
Macrophages impair TLR9 agonist antitumor activity through interacting with the anti-PD-1 antibody Fc domain / S. Camelliti, V. Le Noci, F. Bianchi, C. Storti, F. Arnaboldi, A. Cataldo, S. Indino, E. Jachetti, M. Figini, M.P. Colombo, A. Balsari, N. Gagliano, E. Tagliabue, L. Sfondrini, M. Sommariva. - In: CANCERS. - ISSN 2072-6694. - 13:16(2021 Aug 13), pp. 4081.1-4081.21. [10.3390/cancers13164081]
Macrophages impair TLR9 agonist antitumor activity through interacting with the anti-PD-1 antibody Fc domain
S. CamellitiPrimo
;V. Le Noci;F. Bianchi;C. Storti;F. Arnaboldi;A. Cataldo;S. Indino;M. Figini;M.P. Colombo;A. Balsari;N. Gagliano;E. Tagliabue;L. SfondriniPenultimo
;M. Sommariva
Ultimo
2021
Abstract
Background. A combination of TLR9 agonists and an anti-PD-1 antibody has been reported to be effective in immunocompetent mice but the role of innate immunity has not yet been completely elucidated. Therefore, we investigated the contribution of the innate immune system to this combinatorial immunotherapeutic regimens using an immunodeficient mouse model in which the effector functions of innate immunity can clearly emerge without any interference from T lym-phocytes. Methods. Athymic mice xenografted with IGROV-1 human ovarian cells, reported to be sensitive to TLR9 agonist therapy, were treated with cytosine–guanine (CpG)-oligodeoxynucleo-tides (ODNs), an anti-PD-1 antibody or their combination. Results. We found that PD-1 blockade dampened CpG-ODN antitumor activity. In vitro studies indicated that the interaction between the anti-PD-1 antibody fragment crystallizable (Fc) domain and macrophage Fc receptors caused these immune cells to acquire an immunoregulatory phenotype, contributing to a decrease in the efficacy of CpG-ODNs. Accordingly, in vivo macrophage depletion abrogated the detrimental effect exerted by the anti-PD-1 antibody. Conclusion. Our data suggest that if TLR signaling is active in macro-phages, coadministration of an anti-PD-1 antibody can reprogram these immune cells towards a polarization state able to negatively affect the immune response and eventually promote tumor growth.File | Dimensione | Formato | |
---|---|---|---|
Cancers 2021.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
4.95 MB
Formato
Adobe PDF
|
4.95 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.